Related posts

3 Promising Oversold Stocks3 Best U.S. Healthcare ETFs3 Value Euro Stocks
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Experts are optimistic about Novartis AG (NVS-N) and have recommended it as a top pick with a 9% increase in value. They believe in the company’s prospects and view the recent spinoff as beneficial for business. Additionally, Novartis AG offers an attractive dividend and is regarded as an excellent company overall. Overall, the reviews indicate a positive outlook for the stock.

Consensus
Positive
Valuation
Fair Value
BUY
Novartis AG

If the economy slows down, you need a good pharma stock. Novartis was stuck in a rut until the current CEO started in 2018. He made a number of key acquisitions without paying and including smaller companies (they had overpaid in the past), focusing on their most lucrative divisions: drugs to treat cancer and immunology. he also fired a lot of executives, and hired some outsiders including a smart drug analyst from Wall Street. They sold Roche and pocketed the cash. Bought DTx Pharma, Chinnok Therapeutics, Calypso Biotech and other pharmas offering drug that boast positive trial results. Smart pick-ups, yet disciplined spending, like nixing a deal that cost too much. Their Q1 saw 10% net sales growth and 18% core operating income growth.

biotechnology / pharmaceutical
PAST TOP PICK
Novartis AG
(A Top Pick Apr 18/22, Up 9%)

Will continue to own shares.
Likes prospects for the company.
Recent spinoff good for the business.
Attractive dividend.
Excellent company. 

biotechnology / pharmaceutical
TOP PICK
Novartis AG
Made big money by selling off one division. Decent pipelines. Looking to sell off generic division. Dividend grows, share buybacks. Healthcare has become front and centre, and that's not going away. Safe haven. Underpriced at these levels. Yield is 3.55%. (Analysts’ price target is $88.96)
biotechnology / pharmaceutical
PAST TOP PICK
Novartis AG
(A Top Pick Nov 06/20, Down 1%) They just announced huge inflows after they redeemed their stake in Roche. They continue to do (and will do) more tuck-in acquisitions. And yet, it's a stock that can't get any love. There's no big news in the pipeline. Strong balance sheet. Tuck-ins will continue and it's possible they will spin-off their generics business, so there are catalysts to grow. Cheap now, so it's a buying opportunity.
biotechnology / pharmaceutical
PAST TOP PICK
Novartis AG
(A Top Pick Nov 06/20, Up 3%) He bought it at a really low valuation. Dividend is very safe. Drug pipeline has been a bit slow. More upside from here than the market is reflecting. He's still buying.
biotechnology / pharmaceutical
SELL
Novartis AG
It can't break above $90. He likes a half-dozen drug companies better.
biotechnology / pharmaceutical
TOP PICK
Novartis AG
A joint pharmaceutical company that has two businesses: branded and generic. The generic side will be very interesting post-covid when countries will be indebted and must provide cost-effective health care. The product pipeline looks reasonable. 6% dividend growth in the past 10 years. A safe steady growth opportunity. (Analysts’ price target is $102.00)
biotechnology / pharmaceutical
DON'T BUY
Novartis AG
He sold it recently. They sold their eye-care division and are back to generic drugs, a lousy business for all companies. Invest elsewhere.
biotechnology / pharmaceutical
HOLD
Novartis AG

$200 billion market cap. Fifty + drugs. None of them s over 6.5% of their revenue. They are spinning their ophthalmology business. Some positives there. He struggles to understand why the stock is down. Wouldn’t be his favorite European exposure but still well diversified solid business.

biotechnology / pharmaceutical
BUY
Novartis AG

He likes it because of its exposure to Entresto, which cardiologists often call a wonder drug. The drug is relatively expensive ($9 per day) so the issue is getting insurance companies to pay for it. He thinks the runway for the drug is excellent and that it will become a blockbuster within a year or two. Pharma companies are under pressure because Trump is currently talking about reducing drug prices, but he (Grammer) is willing to wait on this stock.

biotechnology / pharmaceutical
TOP PICK
Novartis AG

It is a very big company with a pipeline of 13 drugs that are close to approves that could be blockbusters. They have drugs for heart failure that cardiologists are keen on. They have an eye care drug. They have a nice mixture of health care drugs. Pharma is unloved but that is an opportunity he can see. (Analysts’ target: $93.00).

biotechnology / pharmaceutical
COMMENT
Novartis AG

This has 3 things going for it. It is an international stock being Swedish, and European stocks have been stronger than US stocks for the 1st time in 10 years, and that should continue. Secondly, it is in healthcare which he likes. Thirdly, they’ve been doing a lot of research in immune boosting therapy, helping people fight cancer. This is going to be huge as we have so much further to go in fighting this scourge.

biotechnology / pharmaceutical
HOLD
Novartis AG

They are joint ventured with Merck. Their oncology business is growing. Their dividend is stable. They are big pharma and you won’t see as much growth out of it. He is in it for the dividend.

biotechnology / pharmaceutical
COMMENT
Novartis AG

A value play that is run out of Switzerland with about a $200 billion market cap. There are 3 drivers to their business. There is the long-standing pharmaceuticals, they have the bio similar business, as well as Alcon for contact lenses. He likes the diversity. They have some key catalysts over the next couple of quarters. They are lacking in immuno ecology, cancer research, and there is speculation that they may sell one of their businesses in order to make an acquisition. Trading at 16X this year and down to just under 15X next year. Stable dividend. He likes this one very much.

biotechnology / pharmaceutical
WATCH
Novartis AG

The global pharma industry is under this cloud. The whole subsector is really struggling. They have come off their bottoms, but are working hard going sideways until we get more clarity on healthcare in the US.

biotechnology / pharmaceutical
Showing 1 to 15 of 46 entries

Novartis AG(NVS-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Novartis AG is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novartis AG(NVS-N) Frequently Asked Questions

What is Novartis AG stock symbol?

Novartis AG is a American stock, trading under the symbol NVS-N on the New York Stock Exchange (NVS). It is usually referred to as NYSE:NVS or NVS-N

Is Novartis AG a buy or a sell?

In the last year, 1 stock analyst published opinions about NVS-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novartis AG.

Is Novartis AG a good investment or a top pick?

Novartis AG was recommended as a Top Pick by on . Read the latest stock experts ratings for Novartis AG.

Why is Novartis AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novartis AG worth watching?

1 stock analyst on Stockchase covered Novartis AG In the last year. It is a trending stock that is worth watching.

What is Novartis AG stock price?

On 2024-06-21, Novartis AG (NVS-N) stock closed at a price of $105.22.